Drug
MP-376 clinical trials
Also written MP-376.
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
7 studies that test it; most in 2008 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 7 · Other 0
Studies
Open first, then newest update. How each study uses MP-376 is read from its arms, and is right about nine times in ten.
Testing it · 7
- Safety, Tolerability and Efficacy of MP-376 Given for 28 Days to Cystic Fibrosis (CF) PatientsCompletedPhase 2AmgenNCT00677365Written as MP-376
- A Phase 2 Study of MP-376 to Prevent Acute Exacerbations in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 2AmgenNCT00739648Written as MP-376
- MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic FibrosisCompletedPhase 3AmgenNCT01180634Written as Aeroquin
- Trial of Aeroquin Versus Tobramycin Inhalation Solution (TIS) in Cystic Fibrosis (CF) PatientsCompletedPhase 3AmgenNCT01270347Written as MP-376 (Levofloxacin Solution for Inhalation)
- A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) PatientsCompletedPhase 1AmgenNCT00752414Written as MP-376 (Levofloxacin solution for Inhalation)
- Safety, Pharmacokinetic and Pharmacodynamic Study of MP-376 in Patients With Cystic FibrosisCompletedPhase 1AmgenNCT00503490Written as MP-376 (Levofloxacin solution for Inhalation)
- "Safety, Tolerability and Pharmacokinetics of MP-376 Administered for 14 Days to Stable Pediatric (CF) Patients"CompletedPhase 1AmgenNCT00840333Written as MP-376 (Levofloxacin solution for Inhalation)